NAD+ research

The NAD+ evidence base cited here is 6 sources — 2 clinical, 4 review. Its strongest evidence is human — 2 clinical studies, most recently 2022 ("Human Whole Blood NAD+ Contents Decrease with Age"). Regulatory status: Not FDA-approved (injectable).

• NAD+ is NOT a peptide — it's a coenzyme (a dinucleotide, ~663 Da) present in every cell, essential for energy production (ATP), DNA repair, and sirtuin activation. Cellular levels decline with age.
• Rapid IV infusion causes a well-known acute reaction (flushing, chest tightness, nausea), which is why clinical infusions are given slowly.

• Attribution for these figures is vague in circulating sources ('various NAD+ infusion studies') — verify against primary literature

• Age-associated NAD+ decline (Massudi et al., 2012, human tissue): ~10–50% decline with age — the rationale for repletion.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.